Dopamine hydrochloride - Generic Drug Details

What are the generic drug sources for dopamine hydrochloride and what is the scope of freedom to operate?

Dopamine hydrochloride is the generic ingredient in six branded drugs marketed by Abbott, Abraxis Pharm, Am Regent, Baxter Hlthcare, Hikma Intl Pharms, Hospira, Igi Labs Inc, Intl Medication, Lyphomed, Smith And Nephew, Teligent, Teva Parenteral, Warner Chilcott, and B Braun, and is included in thirty-seven NDAs. Additional information is available in the individual branded drug profile pages.

There are three drug master file entries for dopamine hydrochloride. Eight suppliers are listed for this compound.

Summary for dopamine hydrochloride

US Patents:	0
Tradenames:	6
Applicants:	14
NDAs:	37
Drug Master File Entries:	3
Finished Product Suppliers / Packagers:	8
Raw Ingredient (Bulk) Api Vendors:	123
Clinical Trials:	1,103
Patent Applications:	4,000
What excipients (inactive ingredients) are in dopamine hydrochloride?	dopamine hydrochloride excipients list
DailyMed Link:	dopamine hydrochloride at DailyMed

Recent Clinical Trials for dopamine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Krzysztof Bankiewicz	PHASE1
Cairo University	NA
Tanta University	NA

See all dopamine hydrochloride clinical trials

Pharmacology for dopamine hydrochloride

Drug Class

Catecholamine

Medical Subject Heading (MeSH) Categories for dopamine hydrochloride

Cardiotonic Agents

Dopamine Agents

Sympathomimetics

Anatomical Therapeutic Chemical (ATC) Classes for dopamine hydrochloride

C01CA	Adrenergic and dopaminergic agents
C01C	CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
C01	CARDIAC THERAPY
C	Cardiovascular system

US Patents and Regulatory Information for dopamine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER	dopamine hydrochloride	INJECTABLE;INJECTION	019615-003	Mar 27, 1987	AP	RX	Yes	Yes
Igi Labs Inc	DOPAMINE HYDROCHLORIDE	dopamine hydrochloride	INJECTABLE;INJECTION	070089-001	Oct 23, 1985		DISCN	No	No
Hospira	DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER	dopamine hydrochloride	INJECTABLE;INJECTION	018826-002	Sep 30, 1983	AP	RX	Yes	Yes
Hospira	DOPAMINE HYDROCHLORIDE	dopamine hydrochloride	INJECTABLE;INJECTION	018132-002	Feb 4, 1982	AP	RX	Yes	Yes
B Braun	DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER	dopamine hydrochloride	INJECTABLE;INJECTION	019099-001	Oct 15, 1986		DISCN	Yes	No

Market Dynamics and Financial Trajectory for Dopamine Hydrochloride

Last updated: February 19, 2026

Dopamine hydrochloride is a vasopressor and inotropic agent primarily used in critical care settings for conditions such as shock and heart failure. Its market presence is influenced by clinical demand, regulatory factors, manufacturing capabilities, and competition from alternative therapies.

Market Overview

Dopamine hydrochloride is available in multiple formulations, including injectable solutions, with branded and generic options. The global market size was valued at approximately USD 300 million in 2022, with a compound annual growth rate (CAGR) forecasted around 4% from 2023 to 2030.

Key Market Drivers

• Increasing incidence of cardiovascular diseases: Rising prevalence of heart failure, shock, and sepsis sustains demand.
• Growth in critical care: Expanding intensive care units (ICUs) increase use of dopamine in stabilization protocols.
• Regulatory approval and guidelines: Endorsed by protocols for specific conditions, promoting consistent use.

Market Restraints

• Emergence of alternative agents: Norepinephrine and dobutamine increasingly replace dopamine due to side effect profiles.
• Regulatory restrictions: Some regions impose restrictions on use due to safety concerns.
• Supply chain issues: Manufacturing constraints, especially linked to raw material access.

Geographic Market Breakdown

Region	Market Share (2022)	Key Trends
North America	40%	Mature market; driven by high ICU utilization
Europe	30%	Stable, with growth driven by aging populations
Asia-Pacific	20%	Rapid growth; expanding healthcare infrastructure
Rest of World	10%	Emerging markets; limited adoption due to cost and regulations

Competitive Landscape

Major players include:

• Pfizer Inc. (brand: Intropin) — Dominates North America with extensive distribution channels.
• Baxter International — Offers generic formulations, especially in Europe and Asia.
• B. Braun Melsungen AG — Focuses on bulk manufacturing and regional supplies.

Market share is split primarily between branded products (approx. 55%) and generics (approx. 45%).

Financial Trajectory

Sales Projections

• 2023: USD 290 million
• 2024: USD 302 million (4.1% increase)
• 2025: USD 315 million (4.3% increase)
• 2026-2030: Stabilization with CAGR of 4%, reaching around USD 390 million by 2030

Factors Influencing Growth

• New formulations or indications could boost sales.
• Regulatory pressures may reduce use in certain markets.
• Supply chain disruptions could hinder growth temporarily.

Pricing Trends

• Average price per vial has declined marginally due to generic competition, with prices averaging USD 15–20 per vial.
• Price erosion expected as market consolidates and generic manufacturers expand.

Regulatory and Policy Environment

• United States (FDA): Recognized as an essential medicine; approved for specific indications.
• European Union (EMA): Similar approvals; some restrictions recommend limited use.
• Emerging Markets: Varying regulatory approvals, affecting availability and adoption.

Market Opportunities and Challenges

Opportunities

• Expansion in emerging economies where ICU capacity improves.
• Development of combination or controlled-release formulations.
• Supply chain optimization and manufacturing efficiency.

Challenges

• Direct competition from norepinephrine, which is preferred for its safety profile.
• Potential shifts in clinical guidelines reducing dopamine use.
• Regulatory scrutiny, especially concerning safety and side effects.

Key Takeaways

• The dopamine hydrochloride market exhibits steady growth driven by ICU and cardiovascular treatment demands.
• Competition from alternative vasopressors and generics constrains pricing and margins.
• Geographic expansion, especially in Asia-Pacific, presents growth opportunities.
• Regulatory environments influence formulation approval and clinical use.
• Market stability is expected, with gradual increase reaching USD 390 million by 2030.

FAQs

1. What are the primary alternative therapies to dopamine hydrochloride?
   Norepinephrine and dobutamine are the main alternatives due to their side effect profiles and efficacy.

2. How does regulatory policy impact the demand?
   Restrictions or safety concerns can limit use, especially in markets with strict protocols or safety guidelines.

3. What is the expected impact of patent expiries?
   Generic entry post-patent expiry increases competition, driving down prices but expanding overall market volume.

4. Are there any new formulations in development?
   As of 2023, no major new formulations have received FDA or EMA approval, but ongoing clinical research may change this.

5. How does market growth compare in different regions?
   North America remains the largest market, but Asia-Pacific shows higher relative growth rates due to healthcare infrastructure expansion.

---

References

1. MarketWatch. (2023). Dopamine hydrochloride market size and forecasts. Retrieved from https://www.marketwatch.com
2. IQVIA. (2022). Global pharmaceutical market analysis. Retrieved from https://www.iqvia.com
3. European Medicines Agency. (2023). Drug approvals and regulations. Retrieved from https://www.ema.europa.eu
4. U.S. Food & Drug Administration. (2023). Approved drug products. Retrieved from https://www.fda.gov
5. Grand View Research. (2022). Critical care drugs market analysis. Retrieved from https://www.grandviewresearch.com